265 related articles for article (PubMed ID: 26791373)
21. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
[TBL] [Abstract][Full Text] [Related]
22. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.
Buchegger F; Garibotto V; Zilli T; Allainmat L; Jorcano S; Vees H; Rager O; Steiner C; Zaidi H; Seimbille Y; Ratib O; Miralbell R
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):68-78. PubMed ID: 24104592
[TBL] [Abstract][Full Text] [Related]
23. Prospective, Multisite, International Comparison of
Emmett L; Metser U; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Punwani S; Pond G; Chua S; Ho B; Johnston E; Pouliot F; Scott AM
J Nucl Med; 2019 Jun; 60(6):794-800. PubMed ID: 30442757
[TBL] [Abstract][Full Text] [Related]
24. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.
Mamede M; Ceci F; Castellucci P; Schiavina R; Fuccio C; Nanni C; Brunocilla E; Fantini L; Costa S; Ferretti A; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2013 Sep; 38(9):e342-5. PubMed ID: 23797218
[TBL] [Abstract][Full Text] [Related]
25. Role of
Jiménez Londoño GA; García Vicente AM; Amo-Salas M; Fúnez Mayorga F; López Guerrero MA; Talavera Rubio MP; Gutierrez Martin P; González García B; de la Torre Pérez JA; Soriano Castrejón ÁM
Rev Esp Med Nucl Imagen Mol; 2017; 36(4):241-246. PubMed ID: 28330596
[TBL] [Abstract][Full Text] [Related]
26. Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting
Yoon J; Ballas L; Desai B; Jadvar H
World J Nucl Med; 2017; 16(3):229-236. PubMed ID: 28670183
[TBL] [Abstract][Full Text] [Related]
27. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.
Breeuwsma AJ; Rybalov M; Leliveld AM; Pruim J; de Jong IJ
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):440-6. PubMed ID: 23069923
[TBL] [Abstract][Full Text] [Related]
28. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
29. A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy.
Tan H; Joseph D; Loh NK; McCarthy M; Leong E; Siew T; Segard T; Morandeau L; Trevenen M; Francis RJ
J Med Imaging Radiat Oncol; 2016 Jun; 60(3):374-81. PubMed ID: 27094471
[TBL] [Abstract][Full Text] [Related]
30. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of
Metser U; Chua S; Ho B; Punwani S; Johnston E; Pouliot F; Tau N; Hawsawy A; Anconina R; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Pond G; Scott AM; Tunariu N; Sidhu H; Emmett L
J Nucl Med; 2019 Sep; 60(9):1253-1258. PubMed ID: 30902875
[TBL] [Abstract][Full Text] [Related]
31. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
von Eyben FE; Kairemo K
Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
[TBL] [Abstract][Full Text] [Related]
32. Metastatic prostate cancer proven by 18F-FCH PET/CT staging scan in patient with normal PSA but high PSA doubling time.
Hodolič M; Maffione AM; Fettich J; Gubina B; Cimitan M; Rubello D
Clin Nucl Med; 2013 Sep; 38(9):739-40. PubMed ID: 23816948
[TBL] [Abstract][Full Text] [Related]
33. 18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.
Vadi SK; Singh B; Basher RK; Watts A; Sood AK; Lal A; Kakkar N; Singh SK
Clin Nucl Med; 2017 Aug; 42(8):e355-e361. PubMed ID: 28525448
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level ≤0.5 ng/mL.
Teyateeti A; Khan B; Teyateeti A; Chen B; Bridhikitti J; Pan T; Peng W; Macapinlac HA; Lu Y
Nucl Med Commun; 2020 Sep; 41(9):906-915. PubMed ID: 32796479
[TBL] [Abstract][Full Text] [Related]
35. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.
Graute V; Jansen N; Ubleis C; Seitz M; Hartenbach M; Scherr MK; Thieme S; Cumming P; Klanke K; Tiling R; Bartenstein P; Hacker M
Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):271-82. PubMed ID: 22086143
[TBL] [Abstract][Full Text] [Related]
36. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Coradeschi E; Bettinardi V; Gianolli L; Scattoni V; Cozzarini C; Di Muzio N; Rigatti P; Fazio F; Messa C
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):301-9. PubMed ID: 19756592
[TBL] [Abstract][Full Text] [Related]
37. Comparison Between
Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience.
Couñago F; Recio M; Maldonado A; Del Cerro E; Díaz-Gavela AA; Thuissard IJ; Sanz-Rosa D; Marcos FJ; Olaciregui K; Mateo M; Cerezo L
Cancer Imaging; 2016 Dec; 16(1):42. PubMed ID: 27927229
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
[TBL] [Abstract][Full Text] [Related]
40. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
